Cargando…
Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significance
The recently developed pathogenic virus, SARS-CoV-2, was found in the Hubei Province, China. Giving rise to a broad spectrum of symptoms, SARS-CoV-2 rapidly spread across the globe, causing multi-systemic and dangerous complications, with death in extreme cases. Thereby, the number of research cases...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492401/ https://www.ncbi.nlm.nih.gov/pubmed/36152703 http://dx.doi.org/10.1016/j.ijbiomac.2022.09.105 |
_version_ | 1784793472500236288 |
---|---|
author | Shirvani, Hanieh Jafari, Hanieh Moravveji, Sayyed Sajjad Abbasi Faranghizadeh, Fatemeh Talebi, Mehrdad Ghanavi, Jalaledin Esfandi, Farbod Najafi, Sajad Nasiri Moghadam, Masomeh Farnia, Poopak Aghaei Zarch, Seyed Mohsen |
author_facet | Shirvani, Hanieh Jafari, Hanieh Moravveji, Sayyed Sajjad Abbasi Faranghizadeh, Fatemeh Talebi, Mehrdad Ghanavi, Jalaledin Esfandi, Farbod Najafi, Sajad Nasiri Moghadam, Masomeh Farnia, Poopak Aghaei Zarch, Seyed Mohsen |
author_sort | Shirvani, Hanieh |
collection | PubMed |
description | The recently developed pathogenic virus, SARS-CoV-2, was found in the Hubei Province, China. Giving rise to a broad spectrum of symptoms, SARS-CoV-2 rapidly spread across the globe, causing multi-systemic and dangerous complications, with death in extreme cases. Thereby, the number of research cases increases every day on preventing infection and treating its resulting damage. Accumulating evidence suggests noncoding RNAs (ncRNAs) are necessary for modifying virus infection and antiviral immune reaction, along with biological processes regulating SARS-CoV-2 and subsequent disease states. Therefore, understanding these mechanisms might provide a further understanding of the pathogenesis and feasible therapy alternatives against SARS-CoV2. Consequently, the molecular biology of SARS-CoV-2, ncRNA's role in its infection, and various RNA therapy tactics against the virus have been presented in this review section. |
format | Online Article Text |
id | pubmed-9492401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94924012022-09-22 Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significance Shirvani, Hanieh Jafari, Hanieh Moravveji, Sayyed Sajjad Abbasi Faranghizadeh, Fatemeh Talebi, Mehrdad Ghanavi, Jalaledin Esfandi, Farbod Najafi, Sajad Nasiri Moghadam, Masomeh Farnia, Poopak Aghaei Zarch, Seyed Mohsen Int J Biol Macromol Review The recently developed pathogenic virus, SARS-CoV-2, was found in the Hubei Province, China. Giving rise to a broad spectrum of symptoms, SARS-CoV-2 rapidly spread across the globe, causing multi-systemic and dangerous complications, with death in extreme cases. Thereby, the number of research cases increases every day on preventing infection and treating its resulting damage. Accumulating evidence suggests noncoding RNAs (ncRNAs) are necessary for modifying virus infection and antiviral immune reaction, along with biological processes regulating SARS-CoV-2 and subsequent disease states. Therefore, understanding these mechanisms might provide a further understanding of the pathogenesis and feasible therapy alternatives against SARS-CoV2. Consequently, the molecular biology of SARS-CoV-2, ncRNA's role in its infection, and various RNA therapy tactics against the virus have been presented in this review section. Published by Elsevier B.V. 2022-12-01 2022-09-22 /pmc/articles/PMC9492401/ /pubmed/36152703 http://dx.doi.org/10.1016/j.ijbiomac.2022.09.105 Text en © 2022 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Shirvani, Hanieh Jafari, Hanieh Moravveji, Sayyed Sajjad Abbasi Faranghizadeh, Fatemeh Talebi, Mehrdad Ghanavi, Jalaledin Esfandi, Farbod Najafi, Sajad Nasiri Moghadam, Masomeh Farnia, Poopak Aghaei Zarch, Seyed Mohsen Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significance |
title | Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significance |
title_full | Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significance |
title_fullStr | Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significance |
title_full_unstemmed | Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significance |
title_short | Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significance |
title_sort | non-coding rna in sars-cov-2: progress toward therapeutic significance |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492401/ https://www.ncbi.nlm.nih.gov/pubmed/36152703 http://dx.doi.org/10.1016/j.ijbiomac.2022.09.105 |
work_keys_str_mv | AT shirvanihanieh noncodingrnainsarscov2progresstowardtherapeuticsignificance AT jafarihanieh noncodingrnainsarscov2progresstowardtherapeuticsignificance AT moravvejisayyedsajjad noncodingrnainsarscov2progresstowardtherapeuticsignificance AT abbasifaranghizadehfatemeh noncodingrnainsarscov2progresstowardtherapeuticsignificance AT talebimehrdad noncodingrnainsarscov2progresstowardtherapeuticsignificance AT ghanavijalaledin noncodingrnainsarscov2progresstowardtherapeuticsignificance AT esfandifarbod noncodingrnainsarscov2progresstowardtherapeuticsignificance AT najafisajad noncodingrnainsarscov2progresstowardtherapeuticsignificance AT nasirimoghadammasomeh noncodingrnainsarscov2progresstowardtherapeuticsignificance AT farniapoopak noncodingrnainsarscov2progresstowardtherapeuticsignificance AT aghaeizarchseyedmohsen noncodingrnainsarscov2progresstowardtherapeuticsignificance |